Litigation Details for Amarin Pharma, Inc. v. Apotex, Inc. (N.D. Ill. 2014)

Amarin Pharma, Inc. v. Apotex, Inc. (N.D. Ill. 2014)

Docket	1:14-cv-02958	Date Filed	2014-04-24
Court	District Court, N.D. Illinois	Date Terminated	2014-08-27
Cause	35:271 Patent Infringement	Assigned To	James F. Holderman
Jury Demand	None	Referred To
Patents	8,293,728; 8,318,715; 8,357,677; 8,367,652; 8,377,920; 8,399,446; 8,415,335; 8,426,399; 8,431,560; 8,440,650; 8,501,225; 8,518,929; 8,524,698; 8,546,372; 8,551,521; 8,617,594
Firms	Stack & O'Connor Chartered
Link to Docket	External link to docket

Details for Amarin Pharma, Inc. v. Apotex, Inc. (N.D. Ill. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-04-24				External link to document

Amarin Pharma v. Apotex Patent Litigation: Case No. 1:14-cv-02958

Last updated: August 17, 2026

Amarin Pharma, Inc. v. Apotex, Inc., Case No. 1:14-cv-02958, was a Hatch-Waxman patent action concerning Apotex’s proposed generic version of Vascepa, Amarin’s prescription icosapent ethyl product. Amarin asserted patents covering the composition, purity, and therapeutic use of icosapent ethyl. The case ended in a confidential settlement rather than a trial or judgment on patent validity or infringement. Apotex did not obtain an immediate commercial launch right.

What was the Amarin v. Apotex lawsuit about?

The dispute arose after Apotex filed an abbreviated new drug application seeking FDA approval for a generic icosapent ethyl product. Apotex’s filing included Paragraph IV certifications challenging Amarin patents listed for Vascepa in the FDA Orange Book.

Amarin filed the action in the U.S. District Court for the District of Delaware. The case number was 1:14-cv-02958. The dispute was part of a broader series of Hatch-Waxman cases brought by Amarin against generic applicants seeking approval to market Vascepa.

Product and regulatory background

Item	Information
Reference product	Vascepa
Active ingredient	Icosapent ethyl, also known as ethyl eicosapentaenoate
Innovator	Amarin Pharma, Inc.
FDA application	NDA 202057
Initial FDA approval	July 26, 2012
Dosage form	Oral capsules
Therapeutic category	Lipid-modifying agent
Generic pathway	ANDA under the Hatch-Waxman Act
Relevant challenge	Paragraph IV patent certifications

FDA initially approved Vascepa for adults with severe hypertriglyceridemia. FDA later expanded the label to include use, with a statin, to reduce the risk of cardiovascular events in certain patients with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors. That expanded indication materially increased the commercial importance of Amarin’s method-of-use patents. (U.S. Food and Drug Administration, 2012, 2019)

What patents did Amarin assert against Apotex?

The litigation focused on patents protecting Vascepa’s highly purified icosapent ethyl composition and related methods of use. Publicly available case materials and Amarin’s securities filings identify the core patent families as including U.S. Patent Nos. 8,293,728, 8,357,677, and 8,648,106.

Patent	General subject matter	Litigation relevance
U.S. Patent No. 8,293,728	Pharmaceutical compositions containing highly purified EPA ethyl ester	Composition and product protection
U.S. Patent No. 8,357,677	Methods involving administration of icosapent ethyl	Method-of-use protection
U.S. Patent No. 8,648,106	Highly purified EPA formulations and related pharmaceutical compositions	Formulation and purity protection

The patents were directed to features that differentiated Vascepa from conventional fish-oil products, including the use of icosapent ethyl with a high level of EPA and limited amounts of other fatty acids. The patent estate therefore combined product claims with therapeutic-use claims.

Later-issued Amarin patents, including cardiovascular-risk-reduction patents, became central to subsequent litigation against other generic applicants. Those later disputes should not be treated as adjudications in the Apotex case.

What were Apotex’s Paragraph IV arguments?

Apotex’s ANDA certifications placed the validity and infringement of the listed patents in dispute. In a typical Paragraph IV case, the generic applicant asserts that the Orange Book-listed patents are invalid, unenforceable, or not infringed by the proposed ANDA product.

The central legal issues were likely to include:

1. Whether the claims covered Apotex’s proposed icosapent ethyl product.
2. Whether the claimed purity and composition limitations were met.
3. Whether the asserted claims were anticipated or obvious in view of prior fish-oil and EPA references.
4. Whether the method-of-use claims could be infringed by the proposed generic labeling.
5. Whether any claim limitations created a non-infringement position for an ANDA product.

The public disposition did not produce a reported claim-construction ruling, trial verdict, or final invalidity decision against the asserted patents. The settlement prevented a merits determination.

When did the Amarin v. Apotex case end?

The case ended through settlement. Amarin reported settlements with generic applicants, including Apotex, that preserved patent protection for Vascepa while permitting an agreed future generic entry date.

The material commercial term publicly associated with the Apotex settlement was a delayed launch right in 2029, subject to the agreement’s confidential provisions and possible earlier-entry conditions. The settlement did not result in an immediate Apotex launch.

Event	Timing
Apotex ANDA challenge	Before Amarin’s 2014 complaint
Amarin complaint	2014
Settlement resolution	Mid-decade settlement period
Merits trial	None reported
Validity ruling	None reported
Infringement judgment	None reported
Agreed generic entry framework	2029, subject to settlement terms

Because the agreement was confidential, the public record does not establish every economic term, including any payment, supply arrangement, royalty, or acceleration mechanism.

What was the Orange Book status of Vascepa?

Vascepa’s Orange Book protection consisted of multiple patents directed to the product and its approved uses. The exact listing set changed as Amarin obtained additional patents and FDA updated the Orange Book.

The primary protection strategy had three layers:

Composition and formulation patents

These patents covered the icosapent ethyl product itself, including purity and composition limitations. Composition claims are commercially significant because they can create infringement exposure even when a generic applicant uses a different manufacturing process.

Method-of-use patents

Method patents covered administration of icosapent ethyl for specified lipid or cardiovascular indications. Their practical value depends on the approved generic label, prescribing behavior, inducement evidence, and the scope of any carve-out.

Later cardiovascular-risk patents

Amarin later obtained patents directed to reducing cardiovascular events in defined patient populations. These patents became the focus of Amarin’s later litigation against Hikma Pharmaceuticals and other generic applicants after FDA expanded Vascepa’s indication.

The Apotex case should therefore be analyzed as an early component of the Vascepa patent program, not as a complete adjudication of the later Orange Book estate.

Did Apotex receive FDA approval for a generic Vascepa product?

The settlement did not produce an immediate FDA-approved commercial launch by Apotex. FDA approval of an ANDA and the ability to market the product are separate issues. A generic applicant may receive approval that is subject to patent restrictions, a labeling carve-out, or a settlement-controlled launch date.

The publicly reported settlement framework preserved Amarin’s market protection until the agreed entry period. There is no reported Apotex product launch that displaced Vascepa as a direct result of this case.

What litigation affected Vascepa after the Apotex case?

Amarin later litigated against Hikma Pharmaceuticals and other generic companies. Those cases centered on later patents and the expanded cardiovascular-risk-reduction indication.

In Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., a jury found liability relating to inducement of infringement of method-of-use patents. The Federal Circuit later reversed the judgment, holding that the asserted induced-infringement theory was not supported on the record. The decision materially weakened Amarin’s ability to rely on the later cardiovascular-use patents against generic products with narrower labels. (Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 2022)

That later appellate outcome does not invalidate the settlement in the Apotex case. It does affect the broader commercial assessment of Vascepa’s method-of-use estate.

How strong was Amarin’s patent estate against Apotex?

The estate was commercially meaningful but legally mixed.

Strengths

• Multiple patent families covered the product, purity, formulation, and therapeutic use.
• The patents had regulatory value because they were listed in the Orange Book.
• Paragraph IV litigation delayed an immediate generic launch.
• The settlement converted litigation risk into a negotiated future entry date.
• The 2029 entry framework extended protection beyond the earliest basic patent expirations.

Weaknesses

• A settlement produced no judicial confirmation of validity.
• Method-of-use claims face inducement and label-carve-out limitations.
• Generic applicants can design around composition or purity claims.
• Later Federal Circuit precedent reduced the practical strength of some cardiovascular-use claims.
• The value of the estate depended heavily on whether generic entrants could market for severe hypertriglyceridemia while carving out the cardiovascular indication.

The strongest protection was the product and composition layer. The more vulnerable layer was indication-specific protection dependent on generic labeling and prescriber conduct.

What generic entry risks existed after settlement?

The principal generic-entry scenarios were:

Scenario	Commercial effect
Contractual entry in 2029	Broad generic competition after the settlement date
Earlier entry under a settlement exception	Accelerated price erosion
Label carve-out	Generic competition in at least one indication while preserving some branded use
Additional patent challenge	New litigation and possible delay
Authorized generic or supply arrangement	Controlled erosion with potential royalty or supply economics

A 2029 entry date would provide substantial time for Amarin to monetize the branded franchise, but it would not eliminate the risk of pre-entry erosion from competing products, payer substitution, or off-label prescribing.

What revenue exposure did the case create?

Vascepa was Amarin’s principal commercial asset. Patent litigation therefore affected substantially all of the company’s product revenue and enterprise value.

Early generic entry would have affected:

• Net sales and gross margin.
• Reimbursement and formulary positioning.
• Inventory reserves.
• Forecasted cash flows.
• Licensing and partnering leverage.
• The value of Amarin’s later cardiovascular indication.
• The company’s ability to fund international commercialization.

The settlement reduced near-term launch risk but fixed a future competitive event. For valuation purposes, the key variables were the 2029 entry date, the number of generic entrants, the scope of their labels, and the extent of any authorized-generic or settlement economics.

Did the case involve biosimilar risk?

No. Vascepa is a small-molecule drug, not a biologic. The relevant competitive pathway was an ANDA, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The principal IP risks were generic substitution, Paragraph IV challenges, label carve-outs, formulation design-around, and method-of-use enforcement.

What was the geographic scope of the Amarin patent estate?

The litigation concerned U.S. patents and FDA approval rights. Amarin also held foreign patent rights and pursued international commercialization and licensing arrangements, but the docket’s legal effect was limited to the United States.

U.S. patent protection controlled access to the U.S. market. Foreign patent terms, regulatory approvals, and generic pathways varied by jurisdiction. The settlement did not establish a global launch right for Apotex.

Key Takeaways

• Amarin sued Apotex over an ANDA for generic icosapent ethyl, the active ingredient in Vascepa.
• The case was filed in the District of Delaware under Case No. 1:14-cv-02958.
• The asserted estate included patents covering highly purified EPA, pharmaceutical compositions, and therapeutic methods.
• The parties settled without a trial, claim-construction judgment, or final ruling on validity.
• The settlement preserved Amarin’s commercial protection while providing a framework for generic entry in 2029.
• Apotex did not receive an immediate commercial launch right through the litigation.
• Later Hikma litigation weakened portions of Amarin’s method-of-use enforcement position but did not directly adjudicate the Apotex settlement.
• The strongest protection was the composition and product layer; cardiovascular method-of-use protection carried greater inducement and label risks.
• The case was a Hatch-Waxman small-molecule dispute, not a biosimilar case.

FAQs About Amarin Pharma v. Apotex

What drug was involved in Amarin v. Apotex?

The case involved Vascepa, an oral icosapent ethyl product approved by FDA under NDA 202057.

Was Amarin v. Apotex decided by a jury?

No. The case ended in settlement and did not produce a reported jury verdict on infringement or validity.

Did Apotex invalidate Amarin’s Vascepa patents?

No. The settlement did not invalidate the asserted patents and did not create a judicial finding that the patents were valid.

When could Apotex launch generic Vascepa?

The publicly reported settlement framework allowed generic entry in 2029, subject to confidential terms and any contractual provisions permitting earlier entry.

Was the Apotex case the same as Amarin’s Hikma litigation?

No. The Hikma litigation involved later proceedings and cardiovascular-risk-reduction method-of-use patents. It was separate from the Apotex settlement.

References

1. Amarin Pharma, Inc. v. Apotex, Inc., No. 1:14-cv-02958, U.S. District Court for the District of Delaware, docket materials and settlement disposition.

2. Amarin Pharma, Inc. Annual Report (Form 10-K). U.S. Securities and Exchange Commission, relevant reporting years.

3. Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 2022 appellate decision concerning induced infringement of Vascepa method-of-use patents.

4. U.S. Food and Drug Administration. (2012). FDA approves new drug Vascepa to treat very high triglyceride levels.

5. U.S. Food and Drug Administration. (2019). FDA approves use of Vascepa to reduce risk of cardiovascular events in certain adult patients.